Loading organizations...
SafeTraces provides a biotech-powered data analytics platform predicting, detecting, and preventing pathogen exposure in indoor environments. Its core offering verifies indoor air quality by actively measuring and mitigating pathogen risk. Utilizing an automated biosensor platform, SafeTraces offers rapid pathogen detection, yielding actionable insights for maintaining healthy, safe indoor spaces.
George Farquar and Anthony Zografos founded SafeTraces in 2013. The company arose from an insight into the critical need for rapid, verifiable environmental safety assurance. This drove the development of technology quickly confirming purity and integrity across various environments, addressing a fundamental public health challenge.
The platform aids organizations implementing robust pathogen mitigation strategies within their facilities. SafeTraces seeks to establish safe, sustainable indoor spaces using definitive data on pathogen risk. Their vision empowers clients to create pathogen-proof environments, fostering occupant well-being and confidence through continuous, evidence-based monitoring.
Safetraces has raised $7.0M across 1 funding round.
Safetraces has raised $7.0M in total across 1 funding round.
Safetraces has raised $7.0M in total across 1 funding round.
SafeTraces is a technology company developing synthetic DNA-based tracers for traceability, authentication, and biosecurity applications across food supply chains, indoor air quality, and pathogen detection. Its core products—veriDART for HVAC and air quality verification, miniDART for on-product food traceability, and saniDART for sanitation validation—serve food producers, healthcare facilities, biopharma, schools, commercial real estate, and critical infrastructure, addressing food safety, counterfeiting, contamination risks, and poor ventilation.[3][4][5] The company solves critical problems like verifying provenance (e.g., organic status, sustainable sourcing), detecting pathogens via rapid PCR readers, and optimizing energy-efficient biosecurity, with early adoption by clients like Borton Fruit for apples and Fortune 100 firms for HVAC commissioning, alongside a $6.5M Series A in 2021 signaling growth momentum.[1][2][4]
SafeTraces' technology originated at Lawrence Livermore National Laboratory, a U.S. Department of Energy facility, where it was developed as a biostimulant for enhancing response to biological agent releases; it pivoted to food traceability using invisible, edible, seaweed-based DNA tags.[1] The company emerged as a startup applying this to commercial food safety, raising $6.5M in Series A funding led by Omidyar Network in 2021, with CEO Anthony Zografos (noted in funding coverage) emphasizing item-level traceability as the "holy grail" for supply chains.[1] Leadership transitioned to current CEO Erik Malmstrom, supported by a diverse team of scientists, engineers, and experts from startups, multinationals, government, and military backgrounds, humanized by their global origins and commitment to safer environments; pivotal early traction includes pilots with apple growers, chocolate producers, and expansions into sanitation verification.[1][5]
SafeTraces rides the post-pandemic biosecurity and supply chain transparency wave, amplifying trends in food safety (e.g., counterfeiting, outbreaks costing billions annually), indoor air quality amid HVAC failures (85% inadequate in California schools), and ESG-driven decarbonization.[2][3][4] Timing aligns with rising demands for verifiable sustainability—organic claims, sustainable sourcing—and tech like qPCR biosensors for rapid pathogen mitigation in high-stakes sectors like healthcare (reducing hospital infections) and biopharma.[2][3] Market forces favor it: regulatory pushes for traceability post-contamination scares, e-commerce straining food logistics, and energy-efficient buildings amid climate goals; it influences the ecosystem by enabling "pathogen-proof" facilities, ROI-maximized mitigations, and first-mover UL VVF certifications for schools.[1][2][3]
SafeTraces is poised to dominate DNA-tracing for hybrid biosecurity-traceability markets, expanding miniDART into pharma/counterfeit drugs and veriDART across global real estate portfolios amid AI-enhanced analytics and federal biodefense needs. Trends like real-time IAQ mandates, food fraud AI integration, and net-zero buildings will accelerate adoption, potentially via strategic partnerships or larger funding rounds. Its lab-to-market evolution positions it to redefine trust in supply chains and environments, turning invisible tracers into visible competitive edges—echoing its "holy grail" promise for safer, verifiable worlds.[1][3][5]
Safetraces has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Series A in October 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2017 | $7.0M Series A |